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Abstract: Background—The Global Asthma Network (GAN) Phase I is surveying school pupils in
high-income and low- or middle-income countries using the International Study of Asthma and
Allergies in Childhood (ISAAC) methodology. Methods—Cross-sectional surveys of participants
in two age groups in randomly selected schools within each centre (2015–2020). The compulsory
age group is 13–14 years (adolescents), optionally including parents or guardians. Six to seven years
(children) and their parents are also optional. Adolescents completed questionnaires at school, and took
home adult questionnaires for parent/guardian completion. Children took home questionnaires
for parent/guardian completion about the child and also adult questionnaires. Questions related
to symptoms and risk factors for asthma and allergy, asthma management, school/work absence
and hospitalisation. Results—53 centres in 20 countries completed quality checks by 31 May 2020.
These included 21 centres that previously participated in ISAAC. There were 132,748 adolescents
(average response rate 88.8%), 91,802 children (average response rate 79.1%), and 177,622 adults,
with >97% answering risk factor questions and >98% answering questions on asthma management,
school/work absence and hospitalisation. Conclusion—The high response rates achieved in ISAAC
have generally been maintained in GAN. GAN Phase I surveys, partially overlapping with ISAAC
centres, will allow within-centre analyses of time-trends in prevalence.
Keywords: global; asthma; surveillance; responses; children; adults’ epidemiology
1. Introduction
The Global Asthma Network (GAN) [1,2] was formed in 2012 as a joint initiative by members of
the International Study of Asthma and Allergies in Childhood (ISAAC) and the International Union
Against Tuberculosis and Lung Disease, following their co-production of the first Global Asthma Report
(GAR), launched in 2011 at the time of the United Nations high-level meeting on non-communicable
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diseases [3]. Estimates of the worldwide burden of asthma in that report were based very largely on the
ISAAC Phase III surveys (2001–2003) of 13–14-year-olds (adolescents) and 6–7-year-olds (children) [4],
with time trends from centres which also participated in ISAAC Phase I (1994–1995) [5], plus the World
Health Surveys of adults (2002–2003) [6]. The need for updated surveillance of asthma prevalence,
severity, diagnosis and management, highlighted in GAR 2011 [3], has become more pressing since
then [7], as very few studies anywhere in the world have evaluated trends in asthma prevalence and
related risk factors over the last decade [8].
GAN Phase I was developed to address this information gap, with these hypotheses:
(1) Globally, the burden of asthma is changing in adults and children;
(2) There is large variation in the diagnosis of asthma;
(3) In many locations, asthma is under-diagnosed and its management is suboptimal; and
(4) There are potentially modifiable risk factors for asthma.
Its aims were:
(1) To conduct asthma surveillance around the world in two age groups of school pupils, and their
parents, measuring prevalence, severity, management and risk factors, following the methods of
ISAAC Phase III;
(2) To examine time trends in prevalence, severity, management and risk factors from centres which
completed ISAAC Phase III; and
(3) To evaluate the appropriateness of asthma management, especially access to quality-assured
essential asthma medicines, as defined by WHO [9].
Although modelled closely on the study design and methodology of ISAAC Phase III, GAN
Phase I has extended its scope to include adults, for whom there are limited global data on asthma
prevalence [8], severity and risk factors, and to assess asthma management, which is commonly
suboptimal in low-income settings [7]. This paper summarises the progress of GAN Phase I at
31 May 2020, when the dataset was temporarily frozen for the first round of analyses including centres
which completed the quality checks by this date.
2. Methods
GAN has collaborators from 383 centres in 137 countries all of whom answered the call for an
Expression of Interest (EOI). Of the EOIs, 136 centres in 58 countries registered to participate in GAN
Phase I. Of these registered centres some have completed GAN Phase I and provided data to this study,
while some, because of timing, will be included in later publications. Other centres have been unable to
undertake Phase I at all because of unforeseen circumstances. Many centres in each of these categories
have contributed to other published GAN surveys [10–13].
GAN Phase I is a cross-sectional, multi-centre, multi-country study undertaken between 2015–2020.
Its methodology has been described and justified elsewhere [2] and detailed in an online manual [14].
Each centre was required to obtain approval from their local ethics committee prior to the start of
their study.
Briefly, each GAN centre is based on a defined geographical area, within which a minimum of
10 schools were selected at random (or all schools, if less than ten). All students of a specified age
within these schools were studied, selected by grade/level/year, or by chronological age. The sample
size estimates of 1000–3000 are stringent because of the number of hypotheses being tested, and high
response rates are sought. As in ISAAC, two age groups of school pupils participated: adolescents and
children. Centres that undertook ISAAC Phase III and/or ISAAC Phase I were expected to use the
same study design and sampling frame in GAN. As in ISAAC Phase III, translations into the local
language were required and centres followed the ISAAC protocol for translation, back translation to
English, and comparison between the two [15].
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The compulsory age group was adolescents, who self-completed written questionnaires at school.
Additionally, in some centres, the ISAAC international video questionnaire showing different scenes of
asthma in children of a variety of ethnicities was shown [16]. A self-completed risk factor questionnaire,
developed for ISAAC Phase III, was strongly recommended in this age group. In ISAAC surveys,
there was no contact with the parents of the adolescent age group, but for GAN, it was recommended
(but not essential) that the parents/guardians of the adolescents were also surveyed.
This optional parental questionnaire obtained information on the prevalence of asthma, rhinitis
and eczema symptoms among adults, plus questions on asthma management and risk factors. The adult
symptoms questionnaire combined items from ISAAC and the European Community Respiratory
Health Survey (ECRHS) [17] to cover the range of chest symptoms and diagnoses that might be related
to asthma in young and middle-aged adults.
The inclusion of children was optional, as with ISAAC Phase III, who took written questionnaires
home to be completed by their parents. These included the ISAAC questionnaire on the child’s
symptoms used in Phases I and III, and the risk factor questionnaire used in Phase III. In GAN it
was recommended (but not essential) to add the parental questionnaire to ascertain the prevalence of
asthma, rhinitis and eczema symptoms among adults in the household.
Data from each centre were submitted to the GAN Global Centre (Auckland, New Zealand)
together with a descriptive centre report. Following initial quality control checks in Auckland, the data
were transferred to one of two designated GAN Phase I data centres for checking and analysis: Murcia
(Spain) for Spanish- and Portuguese-speaking centres, and London (United Kingdom), for centres
using all other languages. A harmonised approach to data processing, checking and analysis was
developed, using Stata versions 13–15.
Estimation of participation rates among children and adolescents followed the conventions
previously adopted in ISAAC Phase III. High levels of participation are sought as it is a concern
that absent school pupils may be away from school due to symptoms of asthma, rhinitis or eczema.
A participation rate of at least 80% for the adolescents and 70% for the children is desirable [2,14].
The denominator was the number of pupils in the cluster sample and the numerator was the number
of core symptom questionnaires returned with at least some symptom data.
We were unable to calculate a conventional response rate for the adults as it was not known
how many adults received questionnaires (because some schoolchildren have only one parent or
guardian). Therefore, a “per child” approach was taken to estimate adult response rate, as follows.
The denominator was the number of school-aged respondents (index schoolchildren) to whom one or
more adult questionnaires were distributed. The numerator was the number of index schoolchildren
for whom one or more adult questionnaires were returned. For centres which distributed adult
questionnaires to both age groups of schoolchildren, the numerators and denominators were combined
to derive a single estimate of “per child” adult response rate.
It was not possible to derive this measure of adult response rate for three centres (Costa Rica
(whole country study), Guatemala City, Guatemala; Tegucigalpa, Honduras) where adult responses
were not linked to the child identifier.
3. Results
By 31 May 2020, 53 centres in 20 countries had submitted and completed quality checks of data
and methodology. Figure 1 shows the location of these centres, also 84 centres in 38 countries which
formally registered an intention to complete GAN Phase I but were unable to do so, and the remaining
GAN collaborating centres. Most centres completed their fieldwork before the onset of the COVID-19
pandemic, but surveys were still active in Iran (Yazd and Karaj) and Greece (Athens) in spring 2020,
where fieldwork was truncated due to school closures in the pandemic lockdown.
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Figure 1. Global Asthma Network (GAN) Centres. Centres registered with GAN identifying those that completed data collection before end of May 2020 (red); 
registered centres expected to complete GAN Phase I later (green); centres collaborating with GAN but not expected to contribute Phase I data (yellow). 
Figure 1. Global Asthma Network (GAN) Centres. Centres registered with GAN identifying those that completed data collection before end of May 2020 (red);
registered centres expected to complete GAN Phase I later (green); centres collaborating with GAN but not expected to contribute Phase I data (yellow).
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Twenty-one of the 53 centres had previously participated in ISAAC Phase III (including 17
contributing data on both age groups) and 12 had previously participated in ISAAC Phase I (including
9 with data on both age groups). All of the 12 ISAAC Phase I centres except for Athens also participated
in ISAAC Phase III. The geographical overlap between ISAAC and GAN centres is shown in Figure 2.
Forty of the 53 GAN centres also contributed data on adult symptoms, risk factors and disease
management, as summarised in Table 1.
Table 2 summarises the numbers of pupils and number of schools for which responses were
received in GAN Phase I, by age group and questionnaire section (symptoms, risk factors, management
and morbidity). When deriving the number of valid responses to the asthma management and
asthma-related morbidity questions, respondents who legitimately skipped these sections because
they had answered negatively to asthma symptoms were included in the count of responders.
Overall, responses were received for 132,748 adolescents attending 1260 schools (with risk factor
information on 99.3% and management/morbidity information on 98.8%) and 91,802 children attending
1506 schools (with risk factor information on 99.3% and management/morbidity information on 99.5%).
Additionally, there were responses for 177,622 adults, with risk factor information on 97.7% and 98.2%
providing information on asthma management, work absence, or hospitalisation. These 177,622 adults
relate to 100,011 school pupils that returned adult questionnaires, comprising 50,416 adolescents and
49,595 children.
The stringent response criteria were able to be met by 45 (85%) of the 53 GAN Phase I centres
for adolescents, 33 (80%) of the 41 GAN Phase I centres for children and by 24 (65%) of the 37 GAN
Phase I centres for adults. Lower rates in some centres occurred due to schools closing because of the
COVID-19 pandemic. Table 3 compares the response rates for the core symptom questionnaires by age
group for each GAN Phase I centre and the corresponding response rates in earlier ISAAC surveys,
where relevant. Across all GAN centres, the mean participation rate was 88.8% for adolescents and
79.1% for children (compared to 88.0% and 84.5%, respectively, in ISAAC Phase III). For GAN Phase I
centres which were also ISAAC Phase III centres, mean response rates were 90.0% for adolescents and
79.0% for children in GAN compared with 89.3% and 84.4%, respectively, in ISAAC Phase III. One
or more responses to the adult symptom questionnaire were received from an average of 73.2% of
households contacted.
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Table 1. Number of study centres contributing data for each GAN Phase I module and age-group, with corresponding data for International Study of Asthma and
Allergies in Childhood (ISAAC) Phases I and III.
GAN Phase I Centres ISAAC Phase III Centres * ISAAC Phase I Centres *
Questionnaire Module 6–7 13–14 Adults 6–7 13–14 6–7 13–14
Symptoms:
Asthma (written) 41 53 40 144 {17} 233 {21} 91 {9} 155 {12}
Asthma (video) NA 29 NA NA 139 {8} NA 99 {3}
Rhinoconjunctivitis 41 53 NA 144 {17} 233 {21} 91 {9} 155 {12}
Eczema 41 53 40 142 {17} 231 {21} 91 {9} 155 {12}
Risk factors:
ISAAC Phase 3 questions 40 52 38 75 {17} 122 {21} ND ND
Active smoking NA 52 38 ND ND ND ND
Perinatal questions 39 NA NA ND ND ND ND
Indoor environment 39 NA 38 ND ND ND ND
Asthma-related:
Management (now) 41 53 40 ND ND ND ND
Management (infancy) 39 NA NA ND ND ND ND
School absence 41 53 40 ND ND ND ND
Work absence NA NA 40 ND ND ND ND
Hospitalisation 41 53 40 ND ND ND ND
* Numbers of centres also participating in GAN Phase I in parentheses. NA Not applicable (module not included for that age group). ND No data (module not included in ISAAC
data collection).
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Figure 2. Overlap of GAN Phase I and ISAAC Centres. Centres that completed GAN Phase I checks before 31 May 2020 (red); GAN Phase I centres included in 
ISAAC Phase III but not ISAAC Phase I (blue); GAN Phase I centres included in ISAAC Phase I and ISAAC Phase III (black*); ISAAC Phase III only centres (white). 
* Athens, Greece contributed data to GAN and ISAAC Phase I, but not ISAAC Phase III. 
Figure 2. Overlap of GAN Phase I and ISAAC Centres. Centres that completed GAN Phase I checks before 31 May 2020 (red); GAN Phase I centres included in ISAAC
Phase III but not ISAAC Phase I (blue); GAN Phase I centres included in ISAAC Phase I and ISAAC Phase III (black*); ISAAC Phase III only centres (white). * Athens,
Greece contributed data to GAN and ISAAC Phase I, but not ISAAC Phase III.
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Table 2. Number of participants (P) and number of schools (S) responding to each GAN module by study centre and age-group.
6–7-Year-Olds 13–14-Year-Olds Adults
Symptoms Risk Factors Management Symptoms Risk Factors Management Symptoms Risk Factors Management
Centre Name P S P S P S P S P S P S P S P S P S
Yaounde 722 27 722 27 703 27 1066 22 1066 22 1056 22 860 32 832 32 824 32
Ibadan 0 0 0 0 0 0 2897 23 2894 23 2810 23 2321 23 2321 23 2217 23
Cape Town 0 0 0 0 0 0 3979 29 3976 29 3879 29 0 0 0 0 0 0
Taipei 3036 25 3036 25 3034 25 3474 24 3465 24 3464 24 9689 49 9673 49 9594 49
Bangkok 3067 7 3067 7 3063 7 3206 6 3201 6 3084 6 5418 13 5416 13 5311 13
Yazd 0 0 0 0 0 0 5141 48 5141 48 5141 48 0 0 0 0 0 0
Karaj 572 39 0 0 572 39 754 42 0 0 754 42 1175 75 0 0 1175 75
Lattakia 1115 9 1078 9 1111 9 1215 10 1214 10 1203 10 0 0 0 0 0 0
Damascus 0 0 0 0 0 0 1100 11 1100 11 1100 11 0 0 0 0 0 0
Kottayam 2099 50 2099 50 2085 50 2090 20 2088 20 2050 20 6940 69 6937 69 6743 69
New Delhi 2516 54 2516 54 2516 54 3024 59 3024 59 3024 59 9449 113 9449 113 9010 113
Chandigarh 2473 57 2473 57 2473 57 3000 54 3000 54 2999 54 10,386 111 10,386 111 10,384 111
Bikaner 2600 45 2600 45 2551 45 2702 33 2702 33 2702 33 10,495 78 10,495 78 10,473 78
Jaipur 2296 44 2296 44 2250 44 3060 57 3057 57 2977 57 8933 101 8902 101 8524 101
iLucknow 2969 32 2969 32 2931 32 2968 31 2969 31 2933 31 11,820 63 11,786 63 11,405 63
Kolkata 0 0 0 0 0 0 2998 37 2998 37 2886 37 7823 91 7818 91 7547 91
Pune 2404 26 2404 26 2403 26 3030 34 3030 34 3021 34 8000 60 7994 60 7909 60
Mysuru (Mysore) 2730 30 2730 30 2730 30 3051 29 3051 29 3051 29 11,178 59 11,178 59 11,177 59
Peradeniya 1492 12 1492 12 1455 12 1696 11 1696 11 1547 11 0 0 0 0 0 0
Anuradhapura 2180 10 2180 10 2120 10 2986 10 2989 10 2638 10 0 0 0 0 0 0
Uruguaiana 0 0 0 0 0 0 1058 17 1052 17 1057 17 896 17 896 17 884 17
Costa Rica 1936 34 1936 34 1936 34 1338 33 1338 33 1316 33 3272 67 3272 67 3102 67
Guatemala City 1072 39 1072 39 1071 39 1420 42 1408 42 1400 42 1078 30 1078 30 1055 29
Tegucigalpa 361 22 361 22 359 22 1431 65 1431 65 1415 65 254 10 254 10 252 10
Mexico City North 2515 58 2515 58 2498 58 3375 9 3370 9 3375 9 5231 66 5219 66 5104 66
Guadalajara 2082 21 2082 21 2075 21 2519 13 2518 13 2516 13 489 20 487 20 483 20
Mexicali 2001 37 2001 37 1999 37 2479 20 2464 20 2469 20 2436 41 2427 41 2427 41
Ciudad Victoria 2444 20 2444 20 2439 20 2468 8 2465 8 2467 8 6239 28 6202 28 6149 28
San Luis Potosí 2108 28 2108 28 2108 28 2580 19 2580 19 2579 19 2835 27 2833 27 2801 27
Tijuana 2082 47 2082 47 2072 47 2601 13 2595 13 2577 13 1397 26 1395 26 1376 26
Toluca Urban 2712 21 2712 21 2702 21 2650 6 2642 6 2643 6 6162 27 6122 27 6072 27
Toluca Rural 2975 17 2976 17 2974 17 3122 16 3114 16 3091 16 7587 33 7583 33 7470 33
Chihuahua 1969 33 1969 33 1962 33 2180 7 2103 7 2161 7 0 0 0 0 0 0
Ciudad Juárez 2117 39 2118 39 2114 39 2443 16 2439 16 2426 16 2610 37 2598 37 2601 37
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Table 2. Cont.
6–7-Year-Olds 13–14-Year-Olds Adults
Symptoms Risk Factors Management Symptoms Risk Factors Management Symptoms Risk Factors Management
Centre Name P S P S P S P S P S P S P S P S P S
Michoácan 2166 39 2166 39 2156 39 2504 14 2502 14 2503 14 2232 39 2232 39 2206 39
Xalapa 3716 83 3717 83 3712 83 3339 21 3335 21 3327 21 0 0 0 0 0 0
Còrdoba 2746 60 2746 60 2738 60 2991 25 2980 25 2989 25 2839 35 2832 35 2829 35
Puerto Vallarta 2241 46 2241 46 2238 46 2439 15 2439 15 2428 15 0 0 0 0 0 0
Aguascalientes 3175 19 3176 19 3165 19 3336 19 3334 19 3331 19 2907 33 2898 33 2861 33
Matamoros 806 24 806 24 799 24 2892 12 2882 12 2865 12 1315 24 1306 24 1298 24
Managua 3162 59 3162 59 3127 59 3131 50 3126 50 2973 50 0 0 0 0 0 0
Prishtina 0 0 0 0 0 0 1054 14 1056 14 1052 14 2006 14 2006 14 1977 14
Gjakova 0 0 0 0 0 0 676 5 676 5 676 5 1352 5 1352 5 1350 5
Prizren 0 0 0 0 0 0 1427 10 1427 10 1427 10 2712 10 0 0 2699 10
Gjilan 0 0 0 0 0 0 1200 6 1200 6 1200 6 1835 6 1835 6 1834 6
Ferizaj 0 0 0 0 0 0 890 9 890 9 885 9 1371 9 1372 9 1328 9
Katowice 1462 36 1462 36 1460 36 3185 29 3184 29 3180 29 2220 35 2219 35 2201 35
Auckland 1538 22 1538 22 1538 22 1885 7 1885 7 1860 7 3002 29 2994 29 2986 29
Athens 0 0 0 0 0 0 1934 20 1934 20 1934 20 1897 20 1897 20 1897 20
Cartagena 3509 61 3509 61 3496 61 3436 26 3430 26 3428 26 6961 60 6956 60 6832 60
Salamanca 2388 51 2388 51 2387 51 3485 31 3484 31 3481 31 0 0 0 0 0 0
Cantabria 2841 75 2841 75 2836 75 4381 47 4372 47 4374 47 0 0 0 0 0 0
A Coruña 3407 48 3407 48 3407 48 3462 26 3461 26 3455 26 0 0 0 0 0 0
All centres 91,802 1506 91,197 1467 91,365 1506 13,2748 1260 131,777 1218 131,179 1260 177,622 1685 173,452 1600 174,367 1684
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Table 3. Response rates for 6–7 and 13–14 year age groups to the written symptom questionnaires in GAN Phase I, ISAAC Phases I and III, by study centre and
age-group. (The adult response rate was estimated on a “per child” basis *).
GAN Phase I ISAAC Phase III ISAAC Phase I
Survey Response (%) Survey Response (%) Survey Response (%)
Country Centre Name Years 6–7 13–14 Adult * Years 6–7 13–14 Years 6–7 13–14
Cameroon Yaounde 2018–19 53.8 99.9 34.6 a
Nigeria Ibadan 2018 - 85.0 79.5 c 2001–02 99.7 1995 76.4
South Africa Cape Town 2017 - 84.4 d 2002 83.4 1995 82.8
Taiwan Taipei 2016–17 76.3 93.0 84.5 a 2001–02 96.8 95.9 1995 92.2 93.2
Thailand Bangkok 2017–18 86.3 97.9 86.1 a 2001 72.8 93.8 1995–96 90.8 74.8
Iran Yazd 2020 - 71.3 d
Iran Karaj 2019–20 72.0 71.9 88.6 a
Syrian Arab Republic Lattakia 2019 93.0 99.6 d 2001–03 99.1 99.8
Syrian Arab Republic Damascus 2018 - 91.7 d
India Kottayam 2017–18 68.4 85.3 97.5 a 2001–03 96.4 98.5 1994–95 78.1 90.7
India New Delhi 2017–18 80.9 100.0 85.7 a 2001–02 82.4 86.7 1994–95 99.2 100
India Chandigarh 2017–18 100.0 100.0 95.5 a 2001–02 99.4 1994–95 94.0 97.4
India Bikaner 2017–18 86.7 90.1 99.8 a 2001 95.4
India Jaipur 2017–18 75.8 98.7 84.4 a 2001 75.4 87.4
India Lucknow 2017 91.3 94.0 99.7 a 2001–02 85.7 75.0
India Kolkata 2017–18 - 99.9 80.2 c
India Pune 2017–18 79.8 99.6 81.4 a 2001–02 90.4 70.8 1994–95 99.6 99.8
India Mysuru (Mysore) 2017–18 90.9 99.5 97.4 a
Sri Lanka Peradeniya 2018 74.6 80.8 d
Sri Lanka Anuradhapura 2018 72.7 85.4 d
Brazil Uruguaiana 2016–18 - 88.2 76.7 c
Costa Rica Costa Rica 2017–18 64.5 66.9 e 2001–02 80.9 69.6 1994–95 84.1 91.4
Guatemala Guatemala City 2018 32.2 40.6 e
Honduras Tegucigalpa 2017–18 76.5 98.0 e
Mexico Mexico City North 2015–16 86.7 93.8 55.9 a 2002–03 91.6 99.8
Mexico Guadalajara 2016 83.3 90.0 12.1 b
Mexico Mexicali 2015–16 77.0 83.7 32.7 a 2002–03 74.3 93.6
Mexico Ciudad Victoria 2015–16 81.5 82.3 78.6 a 2003 73.1 79.5
Mexico San Luis Potosí 2015–16 99.4 97.3 36.7 a
Mexico Tijuana 2015–16 83.3 86.7 41.4 b
Mexico Toluca Urban 2015–16 95.7 98.1 65.5 a
Mexico Toluca Rural 2015–16 93.0 94.6 69.1 a 2002 89.5 86.1
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Table 3. Cont.
GAN Phase I ISAAC Phase III ISAAC Phase I
Survey Response (%) Survey Response (%) Survey Response (%)
Country Centre Name Years 6–7 13–14 Adult * Years 6–7 13–14 Years 6–7 13–14
Mexico Chihuahua 2015–16 87.5 87.2 d
Mexico Ciudad Juárez 2016–17 84.7 88.8 36.7 a
Mexico Michoacán 2016 90.3 92.7 75.8 b
Mexico Xalapa 2016–17 92.9 90.2 d
Mexico Còrdoba 2016 91.5 93.5 30.2 a
Mexico Puerto Vallarta 2015–17 93.4 90.3 d
Mexico Aguascalientes 2015–16 90.7 95.3 44.0 a
Mexico Matamoros 2015–17 80.6 93.3 93.7 b
Nicaragua Managua 2018 87.9 90.5 d 2002 96.0 94.5
Kosovo Prishtina 2017 - 99.9 99.9 c
Kosovo Gjakova 2018 - 90.1 100.0 c
Kosovo Prizren 2017 - 89.0 99.7 c
Kosovo Gjilan 2017 - 80.0 81.5 c
Kosovo Ferizaj 2017 - 99.9 85.1 c
Poland Katowice 2017–18 36.8 79.1 85.6 b
New Zealand Auckland 2018–19 63.7 85.5 51.3 a 2001 84.6 92.3 1992–93 90.2 94.6
Greece Athens 2020 - 75.5 99.9 c 1994–95 87.0
Spain Cartagena 2015–16 65.9 73.8 61.5 a 2001–02 72.3 79.6 1993 68.5 95.1
Spain Salamanca 2017–18 73.7 95.0 d
Spain Cantabria 2017–18 56.2 77.4 d
Spain A Coruña 2018–19 71.0 92.1 d 2003 73.8 93.6
* Adult response rate per child, derived as the percentage of schoolchildren that had one or more adult questionnaires returned, combined across age groups when both age groups were
studied: (a) both age groups; (b) 6–7-year-olds only; (c) 13–14-year-olds only; (d) neither age group; (e) adult responses not linked to child identifiers, so no response rate for adults can
be derived.
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4. Discussion
GAN Phase I has completed fieldwork with data and methodology quality checks in a large
number of centres in both high-income and low- or middle-income countries including representation
from all inhabited continents. This broad geographical coverage is expected to expand as a number of
centres have commenced fieldwork but not yet submitted completed data. However, four countries
(India, Kosovo, Mexico and Spain) account for two-thirds of the datasets received by 31 May 2020
which may limit the international generalisability of the findings.
Overlap between ISAAC and GAN is less extensive than anticipated, but 21 diverse centres will
provide local time-trends in disease prevalence. These within-centre trends can be used, with caution,
to inform projections of trends in prevalence among the remaining centres in ISAAC Phase III,
which offer a much more widespread international representation than has been achieved so far
in GAN.
Careful checks of the methodology used (centre report and data checks), as with ISAAC, ensured
clarity on how the study was actually done and any variations encountered. The high levels of
responses achieved in ISAAC have generally been maintained in GAN, suggesting that estimates of
prevalence and severity of asthma will be representative of the populations surveyed. Sample sizes
in most centres achieved the recommended target of 3000 children per age group, leading to precise
estimates of disease prevalence, but in a few centres the numbers of respondents are substantially
lower (Table 2).
The response rate in both age groups in Guatemala was unusually low (Table 3) and we explored
the possible reasons for this. In both age groups, questionnaires were sent home for completion
by the parents, whereas in other centres, the adolescents self-completed the questionnaires in class.
This probably explains the exceptionally low response rate among 13–14-year-olds in Guatemala.
Extension of ISAAC methodology to include questions about parental symptoms was an attempt
to fill gaps in knowledge about the prevalence, severity, diagnosis and management of asthma and
related risk factors among young and middle-aged adults. Parents of schoolchildren are not a random
or representative sample of the adult population, but the high response rates achieved in many of the
study centres suggest that useful results could be obtained in this manner. The total number of adult
respondents in GAN (177,622) is comparable with two previous international studies of young and
middle-aged adults, discussed below.
The ECRHS, (1991–1993) recruited 137,619 participants aged 20–44 years in 48 centres in 22
countries (including 5 non-European countries: Algeria, Australia, India, New Zealand, USA) [17].
The GAN adult questionnaire incorporates core ECRHS items, but the geographical overlap with
ECRHS countries is limited. The World Health Survey (WHS, 2002–2003) interviewed 178,215 adults
aged 18–45 years from 70 countries and included a few questions about asthma and related symptoms
among a general health questionnaire [6]. Although there is better geographical overlap with GAN,
at least at the country level, the WHS questionnaire lacks detail which limits the scope for historical
comparisons with GAN data on asthma severity.
Among adolescents and children, ISAAC offered a global perspective on time trends in asthma
prevalence from the mid-1990s to the early 2000s [5,18] but very few ISAAC centres have repeated their
local surveys subsequently, prior to GAN. In Brazil, adolescents in Curitiba, Recife and São Paulo were
studied in ISAAC Phases I (1994) and III (2003) and again in 2012 [19] and in South Santiago, Chile,
ISAAC Phases I and III were completed, and a further survey of asthma in adolescents completed in
2015 [20]. Three GAN Phase I studies with previous ISAAC data have been published: in Bangkok,
Thailand, [21] and four Mexican centres [22,23]. Time trends in these centres have been summarised
elsewhere [8].
With the closure of this first round of data in GAN Phase I, these temporal and geographical
comparisons can now be extended to a wider and more diverse range of study centres. These results
will form the basis of analyses for journal publications in the near future. However, GAN centres that
J. Clin. Med. 2020, 9, 3688 13 of 17
were unable to meet the criteria for this first data compilation can still contribute results to future
analyses and publications. The GAN Phase I Study Group is listed at the Appendix A.
In summary, GAN Phase I offers, for the first time in nearly two decades, new standardised
worldwide data on prevalence and severity of asthma in adolescents, children and adults. This will
enable comparisons to be made over time, and contribute a new picture of the global burden of asthma,
rhinoconjunctivitis and eczema. Not only will risk factors be examined, but also time trends in these,
and global variation, shedding light on causation. The methodology which ISAAC started has a proven
track record of over nearly 30 years, and now extends to adults (parents) as well as adolescents and
children. The high response rates achieved in a range of settings are testimony to the feasibility of the
approach and give confidence in the estimates obtained.
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Appendix A
GAN Phase I Study Group
Global Asthma Network Steering Group: I Asher, University of Auckland, Auckland, New Zealand;
N Billo, Joensuu, Finland; K Bissell, School of Population Health, University of Auckland, Auckland,
New Zealand; Chiang C-Y, Division of Pulmonary Medicine, Department of Internal Medicine,
Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; A El Sony, The Epidemiological
Laboratory for Public Health and Research, Khartoum, Sudan; P Ellwood, University of Auckland,
Auckland, New Zealand; L García-Marcos, Virgen de la Arrixaca University Children’s Hospital,
Murcia, Spain; J Mallol, University of Santiago de Chile (USACH), Santiago, Chile; G Marks, University
of New South Wales, Sydney, Australia; K Mortimer, Liverpool School of Tropical Medicine and Aintree
University Hospital NHS Foundation Trust, Liverpool, United Kingdom; N Pearce, London School
of Hygiene and Tropical Medicine, London, United Kingdom; D Strachan, St George’s, University of
London, London, United Kingdom.
Global Asthma Network International Data Centres: Auckland: P Ellwood, E Ellwood, I Asher,
University of Auckland, Auckland, New Zealand; Murcia: V Pérez-Fernández, E Morales, University
of Murcia, Murcia, Spain; L García-Marcos, Pediatric Allergy and Pulmonology Units, ‘Virgen de la
Arrixaca’ University Children’s Hospital, University of Murcia, ARADyAL network and Biomedical
J. Clin. Med. 2020, 9, 3688 14 of 17
Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain; London: C Rutter, R Silverwood,
S Robertson, Neil Pearce, London School of Hygiene & Tropical Medicine, London, United Kingdom;
D Strachan, St George’s, University of London, London, United Kingdom.
Global Asthma Network Principal Investigators: Brazil: M Urrutia-Pereira, Federal University of
Pampa, UNIPAMPA (Uruguaiana); Cameroon: AE Ndikum, The University of Yaounde 1 (Yaounde);
Costa Rica: ME Soto-Quirós, University of Costa Rica (Costa Rica); Greece: K Douros, National and
Kapodistrian University of Athens (Athens); Guatemala: L Pérez-Martini, Asociación Guatemalteca
de Neumología y Cirugía de Tórax (Guatemala City); Honduras: SM Sosa Ferrari, Instituto Nacional
Cardiopulmonar (Tegucigalpa); India: M Sabir, Maharaja Agrasen Medical College Agroha (Bikaner);
M Singh, Postgraduate Institute of Medical Education and Research (Chandigarh); V Singh*,
Asthma Bhawan (Jaipur); AG Ghoshal, National Allergy Asthma Bronchitis Institute (Kolkata (19));
TU Sukumaran, PIMS Thiruvalla (Kottayam); S Awasthi, King George’s Medical University (Lucknow);
PA Mahesh, JSS University (Mysuru); SK Kabra, All India Institute of Medical Sciences (New Delhi);
S Salvi, Chest Research Foundation (Pune); Iran: M Tavakol, Alborz University of Medical Sciences
(Karaj); N Behniafard, Shahid Sadoughi University of Medical Sciences (Yazd); Kosovo: I Bucaliu-Ismajli,
The principal center of family care (Ferizaj); L Pajaziti, (Gjakova); V Gashi, American Hospital in Kosovo
(Gjilan); LN Ahmetaj*, University Hospital of Prishtina (Prishtina); V Zhjeqi, University of Prishtina
(Prizren); Mexico: MG Sanchez Coronel, COMPEDIA (Colegio Mexicano de Pediatras (Aguascalientes);
HL Moreno Gardea, Hospital Angeles Chihuahua (Chihuahua); G Ochoa-Lopez, Department of
Pediatric Allergology (Ciudad Juárez); R García-Almaráz, Hospital Infantil de Tamaulipas (Ciudad
Victoria); JA Sacre Hazouri, Instituto Privado de Alergia, (Córdoba); DD Hernández-Colín, Hospital
Civil De Guadalajara Juan I Menchaca (Guadalajara); N Rodriguez-Perez, Instituto de Ciencias y
Estudios Superiores de Tamaulipas (Matamoros); JV Mérida-Palacio, Centro de Investigacion de
Enfermedades Alergicas y Respiratorias (Mexicali); BE Del Río Navarro*, Service of Allergy and
Clinical immunology, Hospital Infantil de México (Mexico City North); LO Hernández-Mondragón,
CRIT de Michoacán (Michoacán); Md Juan Pineda, Universidad de Guadalajara (Puerto Vallarta);
Bd Ramos García, Instituto Mexicano del Seguro Social (San Luis Potosí); AJ Escalante-Dominguez,
Hospital General Tijuana [Isesalud] (Tijuana); EM Navarrete-Rodriguez, Hospital Infantil de Mexico
Federico Gomez (Toluca Urban); FJ Linares-Zapién, Centro De Enfermedades Alergicas Y Asma
de Toluca (Toluca Rural); J Santos Lozano, Medica san Angel (Xalapa); New Zealand: I Asher,
University of Auckland (Auckland); Nicaragua: JF Sánchez, Hospital Infantil Manuel de Jesús Rivera
(Managua); Nigeria: AG Falade, University of Ibadan and University College Hospital (Ibadan);
Poland: G Brożek, Medical University of Silesia (Katowice); South Africa: HJ Zar, SA MRC Unit
on Child & Adolescent Health (Cape Town); Spain: A Bercedo Sanz, Cantabrian Health Service
(Cantabria); L García-Marcos*, Pediatric Allergy and Pulmonology Units, ‘Virgen de la Arrixaca’
University Children’s Hospital, University of Murcia, ARADyAL network and Biomedical Research
Institute of Murcia (IMIB-Arrixaca), Murcia, Spain (Cartagena); A López-Silvarrey Varela, Fundacion
Maria Jose Jove (La Coruña); J Pellegrini Belinchon, Universidad de Salamanca (Salamanca); Sri Lanka:
JC Ranasinghe, Teaching Hospital Peradeniya (Anuradhapura); ST Kudagammana, University of
Peradeniya (Peradeniya); Syrian Arab Republic: G Alkhayer, Damascus Private University (Damascus);
G Dib, Lattakia University (Lattakia 13–14); Y Mohammad*, National Center for research and training
for chronic respiratory disease and co_morbidities (Lattakia 6–7); Taiwan: J-L Huang, Chang Gung
University (Taipei); Thailand: P Vichyanond*, Mahidol University (Bangkok).
* National Coordinators
Global Asthma Network Adult Age Group Principal Investigators not named above:
Cameroon: GA Ajeagah, The University of Yaounde 1 (Yaounde); Costa Rica: M Soto-Martinez,
University of Costa Rica (Costa Rica); Greece: K Priftis, National and Kapodistrian University of
Athens (Athens); Guatemala: M Cohen-Todd, Asociacion Guatemalteca De Neumologia Y Cirugia De
Torax (Guatemala City); Honduras: J Sanchez, Instituto Nacional Cardiopulmonar (Tegucigalpa); India:
SK Kochar, Sardar Patel Medical College (Bikaner); N Singh, Asthma Bhawan (Jaipur); N Sit, National
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Allergy Asthma Bronchitis Institute (Kolkata (19)); S Sinha, All India Institute of Medical Sciences
(New Delhi); M Barne, Chest Research Foundation (Pune); Kosovo: B Ajeti, The Principal center of
Family Care (Ferizaj); LH Lleshi, (Gjakova); V Lokaj-Berisha, University of Prishtina (Prizren); Mexico:
Md Ambriz-Moreno, (Matamoros); OJ Saucedo-Ramirez, Hospital Angeles Pedregal (Mexico City
North); CA Jiménez González, Universidad Autonoma of San Luis Potosí (San Luis Potosí); Taiwan:
K-W Yeh, (Taipei); Thailand: S Chinratanapisit, Bhumibol Adulyadej Hospital (Bangkok).
Global Asthma Network National Co-ordinators not named above: Brasil: D Solé, Escola Paulista
de Medicina, Federal University of São Paulo, São Paulo.
ISAAC Phase III Principal Investigators: Costa Rica: ME Soto-Quirós*, University of Costa Rica
(Costa Rica); India: M Sabir, Maharaja Agrasen Medical College Agroha (Bikaner); L Kumar
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Department of Pediatrics (Chandigarh); V Singh, Asthma Bhawan (Jaipur); T Sukumaran, PIMS
Thiruvalla (Kottayam); S Awasthi, King George’s Medical University (Lucknow); SK Sharma, All India
Institute of Medical Sciences (New Delhi (7)); NM Hanumante, Ruby Hall Clinic (Pune); Mexico:
R García-Almaráz, Hospital Infantil de Tamaulipas (Ciudad Victoria); JV Merida-Palacio, Centro
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